$-0.14 EPS Expected for Evoke Pharma, Inc. (EVOK)

July 14, 2018 - By Jenna Rose

Evoke Pharma, Inc. (NASDAQ:EVOK) LogoInvestors sentiment decreased to 0.33 in Q1 2018. Its down 1.30, from 1.63 in 2017Q4. It worsened, as 5 investors sold Evoke Pharma, Inc. shares while 4 reduced holdings. 0 funds opened positions while 3 raised stakes. 2.25 million shares or 16.84% less from 2.71 million shares in 2017Q4 were reported.
683 Capital Ltd Llc holds 0.02% of its portfolio in Evoke Pharma, Inc. (NASDAQ:EVOK) for 114,300 shares. Sphera Funds Mgmt Limited, Israel-based fund reported 393,852 shares. The Pennsylvania-based Pnc Svcs Group Inc Inc has invested 0% in Evoke Pharma, Inc. (NASDAQ:EVOK). California Public Employees Retirement System holds 36,700 shares or 0% of its portfolio. Creative Planning, Kansas-based fund reported 100,000 shares. Geode Mngmt Ltd Llc accumulated 23,048 shares or 0% of the stock. Morgan Stanley reported 0% of its portfolio in Evoke Pharma, Inc. (NASDAQ:EVOK). J Goldman L P reported 25,000 shares stake. Knoll Cap Mgmt L P has invested 0.59% of its portfolio in Evoke Pharma, Inc. (NASDAQ:EVOK). Wells Fargo & Communication Mn reported 0% in Evoke Pharma, Inc. (NASDAQ:EVOK). State Treasurer State Of Michigan has 0.01% invested in Evoke Pharma, Inc. (NASDAQ:EVOK). Northern Tru Corp stated it has 0% in Evoke Pharma, Inc. (NASDAQ:EVOK). Vanguard Group reported 0% stake. Blackrock invested 0% in Evoke Pharma, Inc. (NASDAQ:EVOK). 15,566 were accumulated by Utd Cap Fincl Advisers Ltd Liability.

Analysts expect Evoke Pharma, Inc. (NASDAQ:EVOK) to report $-0.14 EPS on August, 13.They anticipate $0.13 EPS change or 48.15 % from last quarter’s $-0.27 EPS. After having $-0.16 EPS previously, Evoke Pharma, Inc.’s analysts see -12.50 % EPS growth. The stock increased 2.27% or $0.06 during the last trading session, reaching $2.7. About 23,135 shares traded. Evoke Pharma, Inc. (NASDAQ:EVOK) has risen 16.02% since July 14, 2017 and is uptrending. It has outperformed by 3.45% the S&P500.

Evoke Pharma, Inc. (NASDAQ:EVOK) Ratings Coverage

Among 2 analysts covering Evoke Pharma (NASDAQ:EVOK), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Evoke Pharma had 6 analyst reports since March 6, 2018 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Monday, April 2. The firm earned “Buy” rating on Thursday, May 3 by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, March 6 by H.C. Wainwright. FBR Capital maintained Evoke Pharma, Inc. (NASDAQ:EVOK) rating on Tuesday, June 5. FBR Capital has “Buy” rating and $500 target. As per Thursday, March 8, the company rating was maintained by FBR Capital. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, June 5.

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. The company has market cap of $45.29 million. It is developing Gimoti, a metoclopramide nasal spray, which completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. It currently has negative earnings.

Evoke Pharma, Inc. (NASDAQ:EVOK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.